Am J Perinatol 1998; 15(11): 643-648
DOI: 10.1055/s-2007-994083
ORIGINAL ARTICLE

© 1998 by Thieme Medical Publishers, Inc.

Liposomal Amphotericin B in Neonates with Invasive Candidiasis

Haider Al Arishi1 , Husn H. Frayha1 , Avedis Kalloghlian2 , Saleh Al Alaiyan3
  • 1Section of Infectious Diseases, Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  • 2Section of Intensive Care, Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  • 3Section of Neonatology, Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Further Information

Publication History

Publication Date:
04 March 2008 (online)

ABSTRACT

Liposomal amphotericin B (L-Amp B), a novel formulation of amphotericin B, is effective for the treatment of invasive fungal infections in children and adults and is associated with less toxicity than the conventional preparation. Data on the use of Liposomal amphotericin B in neonates is scarce. We describe the clinical course of two premature infants who were treated with Liposomal amphotericin B (one infant had candidemia, and the other had candidemia and meningitis), and provide a summary of previously published experience on this topic. Liposomal amphotericin B may be an option for therapy of invasive candidiasis in neonates who are at high risk of nephro-toxicity and other amphotericin-related reactions, but clinical trials are necessary to document its safety and efficacy in this age group.

    >